Displaying items by tag: passives
Active Funds That Only Charge if they Outperform
(New York)
Over the last couple of years there has been a movement on the fringes of the active management space. That movement was towards funds that only charge investors full and/or rising fees if they outperform a given benchmark. If they underperform, their fees would fall back to ETF levels. Well, that idea has taken a big step recently as major fund provider AllianceBernstein has a handful of so-called “fulcrum funds”. The largest is the AB FlexFee Large Cap Growth Advisor Fund, with $106m under management. A top figure at AB put the goals most clearly, saying “The big impact of this will be if we can take money from passive, or money that would’ve gone there … That’s the ultimate goal here”.
FINSUM: Fulcrum funds make a lot of sense for active managers and clients. If the fund managers do their job and seriously outperform a benchmark, then higher fees make sense. If they don’t, then fees stay low.
Fidelity Adds More Free Funds
(New York)
Fidelity is doubling down on its recent move to offer completely free index funds with no investment minimums. The money manager will launch a pair of new free index funds, one focused on large caps, and the other on the “extended market” (or small and midcaps), in late September. The new free funds are part of Fidelity’s strategy to compete vigorously on pricing to bring in new clients, and then try to earn money from them spending on other services.
FINSUM: Fidelity is almost using these funds as loss leaders in order to drum up other business. This may work for them because they have such a large product suite, but for less diversified managers, it poses a serious challenge.
The Best Passive Funds of the Decade
(New York)
Passive funds have seen a meteoric rise since the Financial Crisis, with AUM soaring by trillions. But within that huge growth, what have been the best returning passive funds? Financial Planning produced a slide show presenting the twenty best. The top performing funds list is dominated by the big three providers—BlackRock, Vanguard, and State Street, who also have 82% of all passive AUM. The top five returning funds are the SPDR S&P Biotech (XBI), Invesco Dynamic Pharmaceuticals ETF (PJP), the First Trust NYSE Arca Biotech ETF (FBT), the Invesco Nasdaq Internet ETF (PNQI), and the First Trust Dow Jones Internet ETF (FDN).
FINSUM: Looks like biotech and tech stocks had a great decade (nor surprise there). The rest of the top twenty is similarly dominated by tech and healthcare, but consumer stocks, defense, and semiconductors also show up.
Asset Managers Look Like Major Bargains
(New York)
One of the weakest sectors over the last year has been asset management. If you take a close look at some top asset managers, including Invesco, BlackRock, etc, you will see that many are down 20% or more. The growth of passives, pressure on fees, and weak inflows have all combined to bring down the managers. According to Barron’s they look like big bargains. BlackRock, T.Rowe, Franklin Resources, and Legg Mason look like the good bets. There are some great payers in the group too, with Invesco and BlackRock both sporting yields over 4% and AllianceBernstein paying a whopping 8.6%.
FINSUM: Yes, the industry’s traditional model is under fire, but those with very good scale will win out. Therefore, we do think the very top managers are a good buy, especially at these valuations/yields.